RecruitingNCT06682481

Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function

Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children

Sponsor

Philippe Klee, MD-PhD

Enrollment

50 participants

Start Date

Nov 22, 2024

Study Type

OBSERVATIONAL

Conditions

Obesity, Childhood Type 2 Diabetes Mellitus in Obese

Summary

The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.

Eligibility

Min Age: 12 YearsMax Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This study investigates how the pancreas (specifically the insulin-producing beta cells) and the liver interact in obese children and teenagers, to better understand early-stage changes that can lead to diabetes or fatty liver disease. **You may be eligible if...** - You are between 12 and 16 years old - You are obese (BMI above the 97th percentile for your age) - You or your guardian is able to give informed consent **You may NOT be eligible if...** - You have diabetes with positive autoantibodies (suggesting Type 1 diabetes) - You have a known liver disease other than fatty liver (NAFLD) - You are currently taking diabetes medications, GLP-1 drugs (e.g., Ozempic), or insulin - You are on medications known to affect liver function Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.